Abstract:BACKGROUND: Matrix metalloproteinase-2 (MMP-2) is well known for its critical role in cell survival and cancer development. It also plays an important role in hematopoietic recovery after chemotherapy-induced myelosuppression. In this study, the authors investigated the association of MMP-2 polymorphisms with treatment efficacy and the occurrence of severe toxicity in patients with nonsmall cell lung cancer (NSCLC) who were receiving first-line, platinum-based chemotherapy. METHODS: A pharmacogenetic association study was performed in 663 Chinese patients who had inoperable stage III/IV NSCLC and were receiving first-line, platinum-based regimens. Information about objective response, progression-free survival, overall survival, grade 3 or 4 gastrointestinal toxicity (nausea/vomiting), and hematologic toxicity (neutropenia, anemia, thrombocytopenia) was available. Sixteen tag single nucleotide polymorphisms (SNPs) of MMP-2 were assessed. RESULTS: In 7 polymorphisms, significant associations were observed with the incidence of grade 3 or 4 neutropenia. The variant homozygotes of reference SNP rs12934241 exhibited the most significant effect on the risk of neutropenia, leading to an incidence rate that increased from 12.3% (for the C/C genotype) to 50% (for the T/T genotype; odds ratio, 8.33; P = 8.8 x 10(-5)). Stratified analyses indicated that rs12934241 exhibited a much stronger influence in the cisplatin-gemcitabine regimen subgroup than subgroups that received other regimens (Pinteraction = .003). Further haplotype analyses produced results that were consistent with results from single-SNP analyses. However, no significant association was observed between MMP-2 polymorphisms and treatment efficacy, including response rate, clinical benefit, progression-free survival, and overall survival. CONCLUSIONS: To the authors' knowledge, this study provides the first evidence for a predictive role of MMP-2 polymorphisms in the variability of severe chemotherapy-related neutropenia among Chinese patients with platinum-treated, advanced NSCLC. Cancer 2012;35873598. (C) 2011 American Cancer Society.

Age-related Common Mirna Polymorphism Associated with Severe Toxicity in Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population.

Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer

Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy

MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer.

Genetic Polymorphism of SLC31A1 is Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small-cell Lung Cancer Patients Through Modulating Microrna-Mediated Regulation.

The Association of Genetic Variations in DNA Repair Pathways with Severe Toxicities in NSCLC Patients Undergoing Platinum-Based Chemotherapy.

Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response

Polymorphisms Of Microrna Sequences Or Binding Sites And Lung Cancer: A Meta-Analysis And Systematic Review

Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients

Association of common polymorphisms in p 53 and MDM 2 with platinum-related grade III / IV toxicities in Chinese advanced lung adenocarcinoma patients

Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia

Variations Within 3′-UTR of MDM4 Gene Contribute to Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Following Platinum-Based Chemotherapy

RAD18 Polymorphisms Are Associated with Platinum-Based Chemotherapy Toxicity in Chinese Patients with Non-Small Cell Lung Cancer

Associations Between Genetic Variants Located in Mature Micrornas and Risk of Lung Cancer

Matrix Metalloproteinase-2 Polymorphisms and Clinical Outcome of Chinese Patients with Nonsmall Cell Lung Cancer Treated with First-Line, Platinum-Based Chemotherapy

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

Heterozygote Advantage of Methylenetetrahydrofolate Reductase Polymorphisms on Clinical Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Platinum-Based Chemotherapy

Genetic Polymorphisms in MicroRNA-related Genes As Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients.